Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

ProStrakan Group plc (PSK)

  Print      Mail a friend       Annual reports

Thursday 06 November, 2008

ProStrakan Group plc

Re Agreement

RNS Number : 5575H
ProStrakan Group plc
06 November 2008

Press Release

ProStrakan Group plc

ProStrakan Announces NewBridge Pharmaceuticals as Partner for Sancuso® in the Middle East & Africa

Galashiels, Scotland, 6 November 2008: ProStrakan Group plc, the international specialty pharmaceutical company, today announces that it has signed an exclusive licence and supply agreement with UAE-based NewBridge Pharmaceuticals for Sancuso®, ProStrakan's novel, patent protected transdermal patch for the prevention of chemotherapy-induced nausea and vomiting (CINV), for the Middle East and Africa.

Under the terms of the agreement, covering 59 countries across the Middle East and Africa, ProStrakan will receive undisclosed upfront and milestone payments, subject to the achievement of certain approvals and sales targets. NewBridge will be required to purchase Sancuso directly from ProStrakan at a pre-agreed price. In September 2008, ProStrakan received approval from the US Food and Drug Administration (FDA) for Sancuso and the product was launched in the US this week.

Sancuso is a transdermal patch that delivers granisetron, an established 5HT3 receptor antagonist, steadily into the bloodstream for up to seven days. Sancuso has been shown to be as efficacious as oral granisetron in preventing the side effects of nausea and vomiting in patients undergoing chemotherapy. Sancuso has the advantage of offering this protection through a single transdermal patch application, eradicating the need for repeated daily injections, thus reducing potential infection risk, or having to swallow multiple pills on a repeated daily basis.

Commenting on today's announcement, Dr Wilson Totten, ProStrakan's Chief Executive, said:

"While ProStrakan's core markets are Europe and the US, we continue to seek out opportunities to create a revenue stream from our products in territories that are non-core, yet likely to be lucrative, for us. Our partnership with NewBridge will potentially allow Sancuso to be made available for millions of cancer patients across the Middle East and Africa in order that they too may be relieved of the often distressing effects of chemotherapy-induced nausea and vomiting."

Dr. Garrett Vygantas, Interim Chief Executive Officer of NewBridge Pharmaceuticals, said:

"In partnering with ProStrakan for the Sancuso transdermal system, NewBridge Pharmaceuticals advances further to become one of the key providers of innovative pharmaceutical care to the oncology market in the Middle East and Africa. NewBridge's strategy of providing world-class sales and marketing support for our innovative products allows patients and physicians across the region access to best-in-class therapeutics, devices, medical education and support."



For more information on this announcement, please contact:

ProStrakan Corporate

+44 (0)1896 664000

Dr Wilson Totten, Chief Executive

Callum Spreng, Corporate Communications 

Financial Dynamics

+44 (0)20 7831 3113

David Yates / Ben Brewerton

Trout Group (for US investor enquiries)

Gitanjali Jain

+1 (646) 378-2949

NewBridge Pharmaceuticals

G. Garrett Vygantas, Chief Executive

+1 (415) 591-5483

Burrill & Company

Peter Winter

+1 (415) 591-5474


ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. 

ProStrakan's head office is situated in Galashiels in Scotland. The company's development capabilities are centred on Galashiels and BedminsterNew JerseyUSA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, FranceGermanySpain and other EU countries.

NewBridge Pharmaceuticals

NewBridge Pharmaceuticals ( is a specialty pharmaceutical, biologics, and medical device company serving the Middle East, Africa, Turkey, and Caspian regions to address the unmet needs of diseases with high regional prevalence such as diabetes, obesity, oncology, cardiovascular diseases and other metabolic disorders. NewBridge in-licenses and commercializes FDA and EMEA approved therapeutics and devices. 

Headquartered in UAE with Business Development in the US, NewBridge was founded in 2007 by Burrill & Company, a San Francisco-based Life Science Venture Capital, Private Equity, Merchant Banking and Media firm. NewBridge Pharmaceuticals is uniquely positioned as the partner of choice for pharmaceutical, biotechnology and device companies seeking to capture value from their products in these high growth emerging markets.



This information is provided by RNS
The company news service from the London Stock Exchange